CorMedix Inc. (CRMD) shares soared 5.05% in the pre-market trading session on Wednesday, following Truist Financial analyst Les Sulewski's reiteration of a Buy rating on the stock.

Sulewski's bullish outlook on CorMedix, a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, appears to have sparked investor confidence and driven the stock's price up.

Analysts' ratings and recommendations can significantly influence a stock's price movement, as they reflect expert opinions on a company's prospects and growth potential. A Buy rating from a reputable analyst like Sulewski signals that they expect the stock to outperform the market, prompting investors to buy shares and driving the price higher.